{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:08:31Z","timestamp":1792602511338,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81571780"],"award-info":[{"award-number":["81571780"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012245","name":"Science and Technology Planning Project of Guangdong Province","doi-asserted-by":"publisher","award":["2017B020210004"],"award-info":[{"award-number":["2017B020210004"]}],"id":[{"id":"10.13039\/501100012245","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009330","name":"Medical Science and Technology Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["A2019122"],"award-info":[{"award-number":["A2019122"]}],"id":[{"id":"10.13039\/501100009330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Portal vein tumour thrombus (PVTT)\u2013related symptomatic portal hypertension (SPH) leads to a poor prognosis in hepatocellular carcinoma (HCC) patients. A transjugular intrahepatic portosystemic shunt (TIPS) can effectively relieve SPH but its effect remains unclear in PVTT-related SPH. This study aimed to evaluate the clinical value of the TIPS procedure combined with sequential systemic therapy in advanced HCC patients with PVTT-related SPH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>After 1:1 propensity score matching (PSM), this retrospective study analysed 42 patients who underwent TIPS placement plus sequential systemic therapy (group A) and 42 patients who received only symptomatic and supportive treatment (group B). The evaluated outcomes were overall survival (OS) and SPH control rate. Cox proportional hazards regression analysis was used to compare OS in the two groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In group A, the technical success rate of the TIPS procedure was 95.2%, and no severe complications occurred. The rebleeding rates in group A and group B were 5.0% and 73.7%, respectively (\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001), and the ascites control rates were 92.0% and 28.0%, respectively (\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001). The median OS of group A was significantly better than that of group B (9.6 [95% CI: 7.1, 12.0]\n                      <jats:italic>vs.<\/jats:italic>\n                      4.9 [95% CI: 3.9, 5.8], months,\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001). Multivariable analysis showed that TIPS plus sequential systemic therapy (hazard ratio [HR] = 5.799; 95% CI: 3.177, 10.585;\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001) was an independent prognostic factor related to OS. Additionally, PVTT degree (I+II) (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.008), AFP \u2264 400 ng\/ml (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.003), and Child\u2013Pugh class A (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.046) were significant predictors of OS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>TIPS plus sequential systemic therapy is safe and feasible for treating advanced HCC with tumour thrombus-related SPH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      \u2022\n                      <jats:italic>Portal vein tumour thrombus (PVTT) is common in advanced hepatocellular carcinoma (HCC) and transforms compensated portal hypertension into symptomatic portal hypertension (SPH).<\/jats:italic>\n                    <\/jats:p>\n                    <jats:p>\n                      \u2022\n                      <jats:italic>HCC patients with PVTT-related SPH have a very poor prognosis, and there are no effective treatments recommended by the guidelines.<\/jats:italic>\n                    <\/jats:p>\n                    <jats:p>\n                      \u2022\n                      <jats:italic>Therefore, a treatment strategy that utilises a transjugular intrahepatic portosystemic shunt (TIPS) to manage SPH combined with sequential systemic therapy in advanced HCC patients is explored in this study for its feasibility and clinical value. This research can fill the gap in current research data to provide clinically meaningful treatment options.<\/jats:italic>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00330-022-08705-7","type":"journal-article","created":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T09:03:41Z","timestamp":1650445421000},"page":"6777-6787","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["TIPS plus sequential systemic therapy of advanced HCC patients with tumour thrombus-related symptomatic portal hypertension"],"prefix":"10.1007","volume":"32","author":[{"given":"Zhenkang","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guobao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huzheng","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxuan","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guisong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixiong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingbing","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ligong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fujun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4086-2575","authenticated-orcid":false,"given":"Fei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,20]]},"reference":[{"issue":"10","key":"8705_CR1","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","volume":"16","author":"JD Yang","year":"2019","unstructured":"Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR (2019) A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 16(10):589\u2013604. https:\/\/doi.org\/10.1038\/s41575-019-0186-y","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"5","key":"8705_CR2","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1007\/s00330-017-5145-9","volume":"28","author":"JW Choi","year":"2018","unstructured":"Choi JW, Chung JW, Lee DH et al (2018) Portal hypertension is associated with poor outcome of transarterial chemoembolization in patients with hepatocellular carcinoma. Eur Radiol. 28(5):2184\u20132193. https:\/\/doi.org\/10.1007\/s00330-017-5145-9","journal-title":"Eur Radiol."},{"issue":"2","key":"8705_CR3","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1159\/000450833","volume":"6","author":"HA Ahmed Mohammed","year":"2017","unstructured":"Ahmed Mohammed HA, Yang JD, Giama NH et al (2017) Factors influencing surveillance for hepatocellular carcinoma in patients with liver cirrhosis. Liver cancer. 6(2):126\u2013136. https:\/\/doi.org\/10.1159\/000450833","journal-title":"Liver cancer."},{"key":"8705_CR4","doi-asserted-by":"publisher","unstructured":"Goh KL, Razlan H, Hartono JL et al (2015) Liver cancer in Malaysia: epidemiology and clinical presentation in a multiracial Asian population. J Dig Dis. 16(3):152\u2013158. https:\/\/doi.org\/10.1111\/1751-2980.12223","DOI":"10.1111\/1751-2980.12223"},{"issue":"1","key":"8705_CR5","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L","year":"2018","unstructured":"European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L (2018) EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 69(1):182\u2013236. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.019","journal-title":"J Hepatol."},{"issue":"4","key":"8705_CR6","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1002\/hep.23485","volume":"51","author":"G Cabibbo","year":"2010","unstructured":"Cabibbo G, Enea M, Attanasio M, Bruix J, Craxi A, Camma C (2010) A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology. 51(4):1274\u20131283. https:\/\/doi.org\/10.1002\/hep.23485","journal-title":"Hepatology."},{"issue":"32","key":"8705_CR7","doi-asserted-by":"publisher","first-page":"7289","DOI":"10.3748\/wjg.v22.i32.7289","volume":"22","author":"SL Chan","year":"2016","unstructured":"Chan SL, Chong CC, Chan AW, Poon DM, Chok KS (2016) Management of hepatocellular carcinoma with portal vein tumor thrombosis: review and update at 2016. World J Gastroenterol. 22(32):7289\u20137300. https:\/\/doi.org\/10.3748\/wjg.v22.i32.7289","journal-title":"World J Gastroenterol."},{"issue":"4","key":"8705_CR8","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/00000421-199808000-00014","volume":"21","author":"A Pawarode","year":"1998","unstructured":"Pawarode A, Voravud N, Sriuranpong V, Kullavanijaya P, Patt YZ (1998) Natural history of untreated primary hepatocellular carcinoma: a retrospective study of 157 patients. Am J Clin Oncol. 21(4):386\u2013391. https:\/\/doi.org\/10.1097\/00000421-199808000-00014","journal-title":"Am J Clin Oncol."},{"issue":"1","key":"8705_CR9","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/hep.510290145","volume":"29","author":"JM Llovet","year":"1999","unstructured":"Llovet JM, Bustamante J, Castells A et al (1999) Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 29(1):62\u201367. https:\/\/doi.org\/10.1002\/hep.510290145","journal-title":"Hepatology."},{"issue":"26","key":"8705_CR10","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1200\/JCO.20.00808","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn RS, Ikeda M, Zhu AX et al (2020) Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 38(26):2960\u20132970. https:\/\/doi.org\/10.1200\/JCO.20.00808","journal-title":"J Clin Oncol."},{"issue":"1","key":"8705_CR11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jhep.2017.09.002","volume":"68","author":"D Thabut","year":"2017","unstructured":"Thabut D, Pauwels A, Carbonell N et al (2017) Cirrhotic patients with portal hypertension-related bleeding and an indication for early-TIPS: a large multicentre audit with real-life results. J Hepatol. 68(1):73\u201381. https:\/\/doi.org\/10.1016\/j.jhep.2017.09.002","journal-title":"J Hepatol."},{"issue":"1","key":"8705_CR12","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jhep.2010.06.029","volume":"54","author":"G Han","year":"2011","unstructured":"Han G, Qi X, He C et al (2011) Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis. J Hepatol. 54(1):78\u201388. https:\/\/doi.org\/10.1016\/j.jhep.2010.06.029","journal-title":"J Hepatol."},{"issue":"1","key":"8705_CR13","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/hep.29086","volume":"67","author":"JK Heimbach","year":"2018","unstructured":"Heimbach JK, Kulik LM, Finn RS et al (2018) AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 67(1):358\u2013380. https:\/\/doi.org\/10.1002\/hep.29086","journal-title":"Hepatology."},{"key":"8705_CR14","doi-asserted-by":"publisher","unstructured":"Liu L, Zhao Y, Qi X et al (2014) Transjugular intrahepatic portosystemic shunt for symptomatic portal hypertension in hepatocellular carcinoma with portal vein tumor thrombosis. Hepatol Res. 44(6):621\u2013630. https:\/\/doi.org\/10.1111\/hepr.12162","DOI":"10.1111\/hepr.12162"},{"issue":"9","key":"8705_CR15","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1007\/s00270-017-1655-8","volume":"40","author":"B Qiu","year":"2017","unstructured":"Qiu B, Li K, Dong X, Liu FQ (2017) Transjugular intrahepatic portosystemic shunt for portal hypertension in hepatocellular carcinoma with portal vein tumor thrombus. Cardiovasc Intervent Radiol. 40(9):1372\u20131382. https:\/\/doi.org\/10.1007\/s00270-017-1655-8","journal-title":"Cardiovasc Intervent Radiol."},{"issue":"6","key":"8705_CR16","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.3748\/wjg.v20.i6.1602","volume":"20","author":"JB Zhao","year":"2014","unstructured":"Zhao JB, Feng C, Zhu QH, He XF, Li YH, Chen Y (2014) Transjugular intrahepatic portosystemic shunt with covered stents for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol. 20(6):1602\u20131607. https:\/\/doi.org\/10.3748\/wjg.v20.i6.1602","journal-title":"World J Gastroenterol."},{"issue":"2","key":"8705_CR17","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","volume":"69","author":"European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L","year":"2018","unstructured":"European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L (2018) EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 69(2):406\u2013460. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.024","journal-title":"J Hepatol."},{"issue":"9","key":"8705_CR18","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1097\/00007890-200005150-00023","volume":"69","author":"MA Yerdel","year":"2000","unstructured":"Yerdel MA, Gunson B, Mirza D et al (2000) Portal vein thrombosis in adults undergoing liver transplantation: risk factors, screening, management, and outcome. Transplantation. 69(9):1873\u20131881. https:\/\/doi.org\/10.1097\/00007890-200005150-00023","journal-title":"Transplantation."},{"issue":"1","key":"8705_CR19","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1053\/jhep.2003.50315","volume":"38","author":"KP Moore","year":"2003","unstructured":"Moore KP, Wong F, Gines P et al (2003) The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology. 38(1):258\u2013266. https:\/\/doi.org\/10.1053\/jhep.2003.50315","journal-title":"Hepatology."},{"issue":"10","key":"8705_CR20","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s00535-009-0099-6","volume":"44","author":"U Thalheimer","year":"2009","unstructured":"Thalheimer U, Leandro G, Samonakis DN et al (2009) TIPS for refractory ascites: a single-centre experience. J Gastroenterol. 44(10):1089\u20131095. https:\/\/doi.org\/10.1007\/s00535-009-0099-6","journal-title":"J Gastroenterol."},{"issue":"4","key":"8705_CR21","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359(4):378\u2013390. https:\/\/doi.org\/10.1056\/NEJMoa0708857","journal-title":"N Engl J Med."},{"issue":"10064","key":"8705_CR22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","volume":"389","author":"J Bruix","year":"2017","unstructured":"Bruix J, Qin S, Merle P et al (2017) Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 389(10064):56\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(16)32453-9","journal-title":"Lancet."},{"issue":"10126","key":"8705_CR23","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 391(10126):1163\u20131173. https:\/\/doi.org\/10.1016\/S0140-6736(18)30207-1","journal-title":"Lancet."},{"issue":"4","key":"8705_CR24","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S1470-2045(20)30011-5","volume":"21","author":"S Qin","year":"2020","unstructured":"Qin S, Ren Z, Meng Z et al (2020) Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol. 21(4):571\u2013580. https:\/\/doi.org\/10.1016\/S1470-2045(20)30011-5","journal-title":"Lancet Oncol."},{"issue":"1","key":"8705_CR25","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/hep.28906","volume":"65","author":"G Garcia-Tsao","year":"2017","unstructured":"Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J (2017) Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 65(1):310\u2013335. https:\/\/doi.org\/10.1002\/hep.28906","journal-title":"Hepatology."},{"issue":"4","key":"8705_CR26","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1002\/hep.20386","volume":"40","author":"A Monescillo","year":"2004","unstructured":"Monescillo A, Martinez-Lagares F, Ruiz-del-Arbol L et al (2004) Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology. 40(4):793\u2013801. https:\/\/doi.org\/10.1002\/hep.20386","journal-title":"Hepatology."},{"key":"8705_CR27","doi-asserted-by":"publisher","unstructured":"Garcia-Tsao G, Bosch J (2010) Management of varices and variceal haemorrhage in cirrhosis. N Engl J Med. 362(9):823\u2013832. https:\/\/doi.org\/10.1056\/NEJMra0901512","DOI":"10.1056\/NEJMra0901512"},{"issue":"2","key":"8705_CR28","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/hep.28318","volume":"63","author":"IL Holster","year":"2016","unstructured":"Holster IL, Tjwa ET, Moelker A et al (2016) Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + beta-blocker for prevention of variceal rebleeding. Hepatology. 63(2):581\u2013589. https:\/\/doi.org\/10.1002\/hep.28318","journal-title":"Hepatology."},{"issue":"7","key":"8705_CR29","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1136\/gut.2009.193227","volume":"59","author":"M Rossle","year":"2010","unstructured":"Rossle M, Gerbes AL (2010) TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Gut. 59(7):988\u20131000. https:\/\/doi.org\/10.1136\/gut.2009.193227","journal-title":"Gut."},{"issue":"1","key":"8705_CR30","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1053\/j.gastro.2016.09.016","volume":"152","author":"C Bureau","year":"2017","unstructured":"Bureau C, Thabut D, Oberti F et al (2017) Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites. Gastroenterology. 152(1):157\u2013163. https:\/\/doi.org\/10.1053\/j.gastro.2016.09.016","journal-title":"Gastroenterology."},{"key":"8705_CR31","doi-asserted-by":"publisher","unstructured":"Cabibbo G, Rolle E, De Giorgio M et al (2011) Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib. Expert Rev Anticancer Ther. 11(12):1807\u20131816. https:\/\/doi.org\/10.1586\/era.11.139","DOI":"10.1586\/era.11.139"},{"issue":"12","key":"8705_CR32","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1007\/s00330-015-3777-1","volume":"25","author":"Y Chen","year":"2015","unstructured":"Chen Y, Ye P, Li Y, Ma S, Zhao J, Zeng Q (2015) Percutaneous transhepatic balloon-assisted transjugular intrahepatic portosystemic shunt for chronic, totally occluded, portal vein thrombosis with symptomatic portal hypertension: procedure technique, safety, and clinical applications. Eur Radiol. 25(12):3431\u20133437. https:\/\/doi.org\/10.1007\/s00330-015-3777-1","journal-title":"Eur Radiol."},{"issue":"1","key":"8705_CR33","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/hep.23383","volume":"51","author":"Boyer TD, Haskal ZJ, American Association for the Study of Liver D","year":"2010","unstructured":"Boyer TD, Haskal ZJ, American Association for the Study of Liver D (2010) The Role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension: update 2009. Hepatology. 51(1):306. https:\/\/doi.org\/10.1002\/hep.23383","journal-title":"Hepatology."},{"issue":"3","key":"8705_CR34","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","volume":"63","author":"R de Franchis","year":"2015","unstructured":"de Franchis R, Baveno VIF (2015) Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 63(3):743\u2013752. https:\/\/doi.org\/10.1016\/j.jhep.2015.05.022","journal-title":"J Hepatol."},{"key":"8705_CR35","doi-asserted-by":"publisher","unstructured":"Chen S, Li X, Wei B et al (2013) Recurrent variceal bleeding and shunt patency: prospective randomized controlled trial of transjugular intrahepatic portosystemic shunt alone or combined with coronary vein embolisation. Radiology. 268(3):900\u2013906. https:\/\/doi.org\/10.1148\/radiol.13120800","DOI":"10.1148\/radiol.13120800"},{"key":"8705_CR36","doi-asserted-by":"publisher","unstructured":"Furuse J, Iwasaki M, Yoshino M et al (1997) Hepatocellular carcinoma with portal vein tumor thrombus: embolisation of arterioportal shunts. Radiology. 204(3):787\u2013790. https:\/\/doi.org\/10.1148\/radiology.204.3.9280260","DOI":"10.1148\/radiology.204.3.9280260"},{"issue":"3","key":"8705_CR37","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1177\/0284185117717762","volume":"59","author":"D Yasui","year":"2018","unstructured":"Yasui D, Murata S, Ueda T et al (2018) Novel treatment strategy for advanced hepatocellular carcinoma: combination of conventional transcatheter arterial chemoembolization and modified method with portal vein occlusion for cases with arterioportal shunt: a preliminary study. Acta Radiol. 59(3):266\u2013274. https:\/\/doi.org\/10.1177\/0284185117717762","journal-title":"Acta Radiol."}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-022-08705-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-022-08705-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-022-08705-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T08:03:48Z","timestamp":1663142628000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-022-08705-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,20]]},"references-count":37,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["8705"],"URL":"https:\/\/doi.org\/10.1007\/s00330-022-08705-7","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,20]]},"assertion":[{"value":"9 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The scientific guarantors of this publication are Fei Gao and Fujun Zhang.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No complex statistical methods were necessary for this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was waived by Sun Yat-sen University Cancer Center Institutional Review Board.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This retrospective study was performed in accordance with the Declaration of Helsinki of the World Medical Association. It was approved by Sun Yat-sen University Cancer Center Institutional Review Board (B2020-265), and the informed consent of patients was waived because of its low risk.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"\u2022 retrospective\u2022 case-control study\u2022 performed at one institution","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}